Related Experiment Video
Updated: Sep 18, 2026

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
Published on: January 25, 2016
Role of low-molecular-weight heparins in the treatment of sudden hearing loss
1Department of Otolaryngology, Pingdingshan People's Hospital, No 1, 117 you-yue Road, Pingdingshan City, Henan 467000, P.R. China.
Insights
Low-molecular-weight heparins significantly improve hearing recovery rates in sudden sensorineural hearing loss (SNHL) patients. This treatment offers a safer alternative to unfractionated heparins for SNHL therapy.
Area of Science:
- Otolaryngology
- Pharmacology
Background:
- Sudden sensorineural hearing loss (SNHL) lacks a universally accepted definitive treatment.
- Investigating novel therapeutic agents is crucial for improving SNHL outcomes.
Purpose of the Study:
- To evaluate the efficacy of low-molecular-weight heparins (LMWHs) as an adjunct therapy for SNHL.
- To compare audiometric outcomes in SNHL patients treated with and without LMWHs.
Main Methods:
- Retrospective analysis of 100 SNHL patients divided into two groups.
- Group 1 received standard therapy plus LMWHs; Group 2 received standard therapy alone.
- Audiometric data were compared pre-treatment, at day 10, and at follow-up (average 20 days).
Main Results:
- Significant improvement in early and late audiometric outcomes was observed in the LMWH group (Group 1) compared to the control group (Group 2) (P < .05).
- Recovery or good improvement was noted in 86% of patients in Group 1, significantly higher than in Group 2 (P < .01).
- The average improvement rate was 84% in Group 1.
Conclusions:
- Low-molecular-weight heparins significantly enhance the curative rate for hearing improvement in sudden sensorineural hearing loss.
- LMWHs present a therapeutic option for SNHL without the potential risks associated with unfractionated heparins.
Objective:
For the present, no definitive treatment is universally accepted for sudden sensorineural hearing loss (SNHL). The goal of this study was to evaluate the role of low-molecular-weight heparins in its therapeutic regimen.
Methods:
A retrospective analysis has been taken in 100 patients with SNHL in which they were divided into 2 groups: 50 patients received commonly therapy added with and without low-molecular-weight heparins each. The audiogrametric data at pretreatment were compared with data at day 10 and with data collected at follow-up (average 20 days).
Results:
The results showed that there was a significant improvement for early or late audiometric outcome in group 1 when compared with group 2 (P <.05). Forty-three patients (86%) were classified into recovery or good improvement in group 1, which was higher than group 2 (P <.01). The improvement rate was calculated for each of the 100 patients, and the average value was 84. Seventy percent in group 1 and 70% in group 2.
Conclusion:
It is concluded that the use of low-molecular-weight heparins not only considerably improve the curative rate in the hearing improvement of sudden sensorineural hearing loss but without such potential risk as unfractionated heparins.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
